A new clinical trial has opened recently at several hospitals and has recruited four patients so far. The NEMO study investigates the activity of the drug Nintedabib in a double-blind, randomized phase II study.
Patients can be considered after completing four to six cycles of first line platinum-based chemotherapy for plueral mesothelioma and after confirmation of absence of progressive disease.
Recruiting sites are at:
Weston Park Hospital, Sheffield
Royal Marsden Hospital, Chelsea, London
Royal Marsden Hospital, Sutton, Surrey
South Tyneside District Hospital
UHSM Wythenshawe Hospital
and Royal Marsden Hospital, Kingston Hospital.
These centres are in set-up and will open in due course:
St James’ University Hospital, Leeds
Mount Vernon Hospital, Hertfordshire
Musgrove Park Hospital, Taunton
More details can be found at www.mesothelioma.uk.com/informationandsupport